Hidden aggressive cells found in lower-risk RMS tumors — SkimNews
Get the Health newsletter
Daily health & science — research, biotech, public health, the studies worth knowing. Free.
- Wellcome Sanger Institute researchers, working with the University of Cambridge, GOSH and UCL, compared tumors from 16 children: four PAX-FOXO1-negative cases proved fatal, four tumors were fusion-positive, and eight fusion-negative children remained alive.
- Single-cell RNA sequencing measured gene activity cell by cell and exposed aggressive populations that conventional methods miss, including within some tumors classified as non-high-risk.
- Spatial transcriptomics mapped gene activity to tumor locations and showed that aggressive cells in some non-high-risk tumors closely resembled the gene-activity patterns of high-risk disease.
- Karin Straathof said that, although the hidden aggressive tumors carried different genetic changes, many converged on the same cellular pathways, demonstrating multiple genetic routes to a shared aggressive state.
- Sam Behjati said the shared biology could help identify children needing more intensive treatment regardless of the mutation driving their tumors, while genuinely lower-risk children could avoid some chemotherapy side effects.
- The research team is expanding the analysis to hundreds of additional rhabdomyosarcoma samples to uncover more rare genetic changes and accelerate development of personalized treatments.
Why it matters: For the roughly 55 children diagnosed with rhabdomyosarcoma in the UK each year, the source says a cell-state assessment could direct intensive therapy toward hidden high-risk disease while sparing genuinely lower-risk children chemotherapy’s harmful side effects. The work still needs validation in hundreds more samples before routine clinical use.
Ask SkimNews
